Tokushima University / Educator and Researcher Directory --- Ohzono, Mizune

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Seiko Nakamura, Mizune Ohzono, Karen Yanagi and Kentaro Kogure : Development of an effective psoriasis treatment by combining tacrolimus-encapsulated liposomes and iontophoresis, Biological & Pharmaceutical Bulletin, Vol.47, No.1, 196-203, 2023. (Summary) Psoriasis is a chronic T-cell-mediated autoimmune skin disease. Tacrolimus (FK506) is commonly used treatment for psoriasis. However, since the molecular weight of FK506 is more than 500 Da, its skin penetration is limited, so that there is a need to improve the penetrability of FK506 to allow for more effective treatment. To this end, we employed iontophoresis (ItP), which is a physical, intradermal drug delivery technology that relies on the use of weak electric current. Previous findings suggest that activation of cell signaling by the weak electric current applied during ItP may affect the expression of inflammatory cytokines, leading to aggravation of psoriasis. In this study, we analyzed the effect of ItP on the expression of various inflammatory cytokines in the skin, and subsequently examined the therapeutic effect of ItP using negatively-charged liposomes encapsulating FK506 (FK-Lipo) in a rat psoriasis model induced by imiquimod. We found that ItP (0.34 mA/cm, 1 h) did not affect mRNA levels of inflammatory cytokines or epidermis thickness, indicating that ItP is a safe technology for psoriasis treatment. ItP of FK-Lipo suppressed the expression of inflammatory cytokines induced by imiquimod treatment to a greater extent than skin treated with FK506 ointment for 1 h. Furthermore, epidermis thickening was significantly suppressed only by ItP of FK-Lipo. Taken together, results of this study demonstrate the successful development of an efficient treatment for psoriasis by combining FK-Lipo and ItP, without disease aggravation associated with the weak electric current. (Tokushima University Institutional Repository) ● Metadata: 118787 (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b23-00667 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38246645 ● Search Scopus @ Elsevier (PMID): 38246645 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b23-00667 (Tokushima University Institutional Repository: 118787, DOI: 10.1248/bpb.b23-00667, PubMed: 38246645)
2.	Manobendro Nath Ray, Michiko Kiyofuji, Mizune Ohzono and Kentaro Kogure : Vitamin E succinate mediated apoptosis by juxtaposing endoplasmic reticulum and mitochondria, Biochimica et Biophysica Acta (BBA) - General Subjects, Vol.1867, No.12, 130485, 2023. (Summary) Vitamin E succinate (VES) is an esterified form of natural α-tocopherol, has turned out to be novel anticancer agent. However, its anticancer mechanisms have not been illustrated. Previously, we reported VES mediated Ca release from the endoplasmic reticulum (ER) causes mitochondrial Ca overload, leading to mitochondrial depolarization and apoptosis. Here, we elucidated the mechanism of VES-induced Ca transfer from ER to mitochondria by investigating the role of VES in ER-mitochondria contact formation. Transmission electron microscopic observation confirms VES mediated ER-mitochondria contact while fluorescence microscopic analysis revealed that VES increased mitochondria-associated ER membrane (MAM) formation. Pre-treatment with the inositol 1,4,5-triphosphate receptor (IPR) antagonist 2-aminoethyl diphenylborinate (2-APB) decreased VES-induced MAM formation, suggesting the involvement of VES-induced Ca efflux from ER in MAM formation. The ER IPR receptor is known to interact with voltage-dependent anion channels (VDAC) via the chaperone glucose-regulated protein 75 kDa (GRP75) to bring ER and mitochondria nearby. Although we revealed that VES treatment does not affect GRP75 protein level, it increases GRP75 localization in the MAM. In addition, the inhibition of Ca release from ER by 2-APB decreases GRP75 localization in the MAM, suggesting the possibility of Ca-induced conformational change of GRP75 that promotes formation of the IPR-GRP75-VDAC complex and thereby encourages MAM formation. This study identifies the mechanism of VES-induced enhanced Ca transfer from ER to mitochondria, which causes mitochondrial Ca overload leading to apoptosis. (Keyword) alpha-Tocopherol / Mitochondria / Endoplasmic Reticulum / Apoptosis (Tokushima University Institutional Repository) ● Metadata: 118618 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbagen.2023.130485 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37838355 ● Search Scopus @ Elsevier (PMID): 37838355 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbagen.2023.130485 (Tokushima University Institutional Repository: 118618, DOI: 10.1016/j.bbagen.2023.130485, PubMed: 37838355)
3.	Rabab A. Husseini, Tatsuya Fukuta, Mizune Ohzono, Azza A. Hasan, Nagia El A. Megrab and Kentaro Kogure : The effect of iontophoretic-delivered polyplex vaccine on melanoma regression, Biological & Pharmaceutical Bulletin, Vol.46, No.3, 494-504, 2023. (Summary) Although the strategy in cancer vaccination is to provide a therapeutic effect against an established tumor, there is an urgent need to develop prophylactic vaccines for non-viral cancers. In this study, we prepared polyplex nanoparticles through electrostatic interactions between a positively-charged modified tumor associated antigen, namely human derived melanoma gp100 peptide (KVPRNQDWL-RRRR), and a negatively charged cytosine-phosphate-guanosine motif (CpG-ODN) adjuvant. We previously demonstrated successful transdermal delivery of various hydrophilic macromolecules by iontophoresis (IP) using weak electricity. Herein, we investigated the effectiveness of IP in the transdermal delivery of a prophylactic polyplex vaccine. IP was successful in establishing a homogenous distribution of the vaccine throughout skin. Efficacy of the vaccine was demonstrated against melanoma growth. A significant tumor regression effect was observed, which was confirmed by elevated mRNA expression levels of various cytokines, mainly interferon (IFN)-γ, as well as infiltration of cytotoxic CD8 T cells. Additionally, we evaluated the therapeutic effect of the vaccine and we found a significant reduction in tumor burden. Stimulation of systemic immunity was confirmed by upregulation of IFN-γ. This is the first report to demonstrate the use of IP in the transdermal delivery of a prophylactic melanoma vaccine. (Keyword) Humans / Iontophoresis / CD8-Positive T-Lymphocytes / Melanoma / Cancer Vaccines / Interferon-gamma (Tokushima University Institutional Repository) ● Metadata: 117908 (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b22-00873 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36858579 ● Search Scopus @ Elsevier (PMID): 36858579 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b22-00873 (Tokushima University Institutional Repository: 117908, DOI: 10.1248/bpb.b22-00873, PubMed: 36858579)
4.	Ray Nath Manobendro, Mizune Ohzono, Michiyasu Nakao, Shigeki Sano and Kentaro Kogure : Only one carbon difference determines the pro-apoptotic activity of α-tocopheryl esters, The FEBS Journal, Vol.290, 1027-1048, 2023. (Summary) α-Tocopheryl succinate (TS), a redox-silent succinyl ester of natural α-Tocopherol, has emerged as a novel anti-cancer agent. However, the underlying mechanism is unclear. We found that the terminal dicarboxylic moiety of tocopheryl esters contributes to apoptosis induction and thus cytotoxicity. To further examine this relationship, we compared the pro-apoptotic activity of TS, which has four carbon atoms in the terminal dicarboxylic moiety, to that of a newly synthesized, tocopheryl glutarate (Tglu), which has five. Cytotoxicity assays in vitro confirmed that TS stimulated apoptosis, while Tglu was non-cytotoxic. In investigating biological mechanisms leading to these opposing effects, we found that TS caused an elevation of intracellular superoxide, but Tglu did not. TS increased intracellular Ca in cultured cells, suggesting induction of endoplasmic reticulum (ER) stress; however, Tglu did not affect Ca homeostasis. 1,4,5-trisphosphate (IP ) receptor antagonist 2-Aminoethyl diphenylborinate (2-APB) decreased TS-induced intracellular Ca , restored mitochondrial activity and cell viability in TS-treated cells, establishing the ER-mitochondria relationship in apoptosis induction. Moreover, real-time PCR, immunostaining and Western blotting assays revealed that TS downregulated glucose-regulated protein 78 (GRP78), which maintains ER homeostasis and promotes cell survival. Conversely, Tglu upregulates GRP78. Taken together, our results suggest a model in which TS-mediated superoxide production and GRP78 inhibition induce ER stress, which elevates intracellular Ca and depolarizes mitochondria, leading to apoptosis. Because Tglu does not affect superoxide generation and increases GRP78 expression, it inhibits ER stress and is thereby non-cytotoxic. Our research provides insight into the structure-activity relationship of tocopheryl esters regarding the induction of apoptosis. (Tokushima University Institutional Repository) ● Metadata: 117788 (Link to Publication Site) ● Publication site (DOI): 10.1111/febs.16623 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36083714 ● Summary page in Scopus @ Elsevier: 2-s2.0-85138289941 (Tokushima University Institutional Repository: 117788, DOI: 10.1111/febs.16623, PubMed: 36083714, Elsevier: Scopus)
5.	El-Emam Mohamed Abd Mahran, Ray Nath Manobendro, Mizune Ohzono and Kentaro Kogure : Heat stress disrupts spermatogenesis via modulation of sperm-specific calcium channels in rats, Journal of Thermal Biology, Vol.112, 103465, 2023. (Summary) Heat is a detrimental environmental stressor that disrupts spermatogenesis and results in male infertility. Previous investigations have shown that heat stress reduces the motility, number, and fertilization ability of living spermatozoa. Sperm hyperactivation, capacitation, acrosomal reaction, and chemotaxis towards the ova are regulated by the cation channel of sperm (CatSper). This sperm-specific ion channel triggers the influx of calcium ions into sperm cells. The aim of this study in rats was to investigate whether heat treatment affected the expression levels of CatSper-1 and -2, together with the sperm parameters, testicular histology and weight. The rats were exposed to heat stress for 6 days and the cauda epididymis and testis were collected 1, 14, and 35 days after heat treatment to measure sperm parameters, gene and protein expression, testicular weight, and histology. Interestingly, we found that heat treatment caused a notable downregulation of CatSper-1 and -2 expression at all three time points. In addition, there were significant reductions in sperm motility and number and an increase in the percentage of abnormal sperm at 1 and 14 days, with cessation of sperm production at 35 days. Furthermore, expression of the steroidogenesis regulator, 3 beta-hydroxysteroid dehydrogenase (3β-HSD) was upregulated in the 1-, 14- and 35-day samples. Heat treatment also upregulated the expression of the apoptosis regulator, BCL2-associated X protein (BAX), decreased testicular weight, and altered testicular histology. Therefore, our data showed for the first time that heat stress downregulated CatSper-1 and -2 in the rat testis, and that this may be a mechanism involved in heat stress-induced impairment of spermatogenesis. (Keyword) Male / Rats / Animals / Calcium Channels / Semen / Sperm Motility / Spermatozoa / Spermatogenesis / Testis / Calcium (Tokushima University Institutional Repository) ● Metadata: 117909 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jtherbio.2023.103465 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36796910 ● Search Scopus @ Elsevier (PMID): 36796910 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jtherbio.2023.103465 (Tokushima University Institutional Repository: 117909, DOI: 10.1016/j.jtherbio.2023.103465, PubMed: 36796910)
6.	Ara Tabassum, Satoko Ono, M Hasan, Mizune Ohzono and Kentaro Kogure : Protective effects of liposomes encapsulating ferulic acid against CCl4-induced oxidative liver damage in vivo rat model, Journal of Clinical Biochemistry and Nutrition, Vol.72, No.1, 46-53, 2023. (Summary) Antioxidants are useful for the treatment of oxidative stress mediated liver damage. A naturally occurring antioxidant γ-oryzanol is rapidly hydrolyzed to its active hydrophobic metabolite, ferulic acid, inside the body. Limitations associated with the hydrophobicity of ferulic acid can be overcome by encapsulating in a liposomal formulation. As intravenously administered nanoparticles (including liposomes) can effectively reach the liver, such systems may be suitable drug delivery carriers to treat liver injury. In this study, we prepared a liposomal formulation of ferulic acid (ferulic-lipo) and examined its effects on liver damage induced by CCl. Ferulic-lipo were ~100 nm in size and drug encapsulation efficiency was about 92%. Ferulic-lipo showed potent scavenging efficacy against hydroxyl radical compared to α-tocopherol liposomes. Ferulic-lipo significantly prevented CCl-mediated cytotoxicity in human hepatocarcinoma cells. Furthermore, intravenous administration of ferulic-lipo significantly reduced alanine aminotransferase and aspartate amino transferase levels in a rat model of liver injury. CCl-mediated reactive oxygen species generation in liver was also reduced by intravenous administration of ferulic-lipo. Hepatoprotective effects of ferulic-lipo were demonstrated by histological observation of CCl-induced liver tissue damage. Therefore, ferulic-lipo exhibit potent antioxidative capacity and were suggested to be an effective formulation for prevention of oxidative damage of liver tissue. (Tokushima University Institutional Repository) ● Metadata: 117266 (Link to Publication Site) ● Publication site (DOI): 10.3164/jcbn.22-37 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36777075 ● CiNii @ National Institute of Informatics (CRID): 1390576118542264832 ● Summary page in Scopus @ Elsevier: 2-s2.0-85146549828 (Tokushima University Institutional Repository: 117266, DOI: 10.3164/jcbn.22-37, PubMed: 36777075, CiNii: 1390576118542264832, Elsevier: Scopus)
7.	Misaki Yamasaki, Yuika Seto, Mizune Ohzono, Michiyasu Nakao, Akira Shigenaga, Akira Otaka, Shigeki Sano and Kentaro Kogure : Development of a novel tocopheryl ester for suppression of lipid accumulation without cytotoxicity by optimization of dicarboxylic ester moiety, Biochemistry and Biophysics Reports, Vol.31, 101329, 2022. (Tokushima University Institutional Repository) ● Metadata: 117361 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbrep.2022.101329 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbrep.2022.101329 (Tokushima University Institutional Repository: 117361, DOI: 10.1016/j.bbrep.2022.101329)
8.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : Enhancement of cerebroprotective effects of lipid nanoparticles encapsulating FK506 on cerebral ischemia/reperfusion injury by particle size regulation, Biochemical and Biophysical Research Communications, Vol.611, 53-59, 2022. (Summary) Delivery of cerebroprotective agents using liposomes has been demonstrated to be useful for treating cerebral ischemia/reperfusion (I/R) injury. We previously reported that intravenous administration of liposomes with diameters of 100 nm showed higher accumulation in the I/R region compared with larger liposomes (>200 nm) by passage through the disintegrated blood-brain barrier, suggesting a size-dependence for liposome-mediated drug delivery. Based on these findings, we hypothesized that regulation of liposomal particle size (<100 nm) may enhance the therapeutic efficacy of encapsulated drugs on cerebral I/R injury. Herein, we prepared lipid nanoparticles (LNP) with particle sizes <100 nm by the microfluidics method and compared their therapeutic potential with LNP exhibiting sizes >100 nm in cerebral I/R model rats. Intravenously administered smaller LNP (ca. 60 nm) exhibited wider accumulation and diffusivity in the brain parenchyma of the I/R region compared with larger LNP (>100 nm). Importantly, treatment with LNP encapsulating the cerebroprotective agent FK506 (FK-LNP) with particle sizes <100 nm showed greater cerebroprotective effects than FK-LNP with sizes >100 nm, and also significantly ameliorated brain injury. These results suggest that particle size regulation of LNP to sizes <100 nm can enhance the therapeutic effect of encapsulated drugs for treatment of cerebral I/R injury, and that FK-LNP could be a promising cerebroprotective agent. (Keyword) Animals / Brain Ischemia / Liposomes / Nanoparticles / Neuroprotective Agents / Particle Size / Rats / Rats, Wistar / Reperfusion Injury / Tacrolimus (Tokushima University Institutional Repository) ● Metadata: 117238 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbrc.2022.04.080 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35477093 ● Search Scopus @ Elsevier (PMID): 35477093 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbrc.2022.04.080 (Tokushima University Institutional Repository: 117238, DOI: 10.1016/j.bbrc.2022.04.080, PubMed: 35477093)
9.	Yuma Hirata, Riho Tashima, Naoto Mitsuhashi, Shintaro Yoneda, Mizune Ohzono, Eiji Majima, Tatsuya Fukuta and Kentaro Kogure : A simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes, International Journal of Pharmaceutics, Vol.607, No.25, 120966, 2021. (Summary) Modification with antibodies is a useful strategy for the delivery of nanoparticles to target cells. However, the complexity of the required chemical modifications makes them time-consuming and low efficiency, and the orientation of the antibody is challenging to control. To develop a simple, fast, effective, and orientation-controllable technology, we employed staphylococcal protein A, which can bind to the Fc region of antibodies, as a tool for conjugating antibodies to nanoparticles. Specifically, we modified the C-domain dimer of protein A to contain a lysine cluster to create a molecule, DPACK, that would electrostatically bind to anionic liposomes. Using this protein, antibody-modified liposomes can be prepared in 35 min with two steps: (1) interaction of DPACK with liposomes and (2) interaction of an antibody with DPACK-modified liposomes. Binding efficiencies of DPACK with liposomes and IgG with DPACK-modified liposomes were 75% and 72-84%, respectively. Uptake of liposomes modified with anti-epidermal growth factor receptor (EGFR) antibodies via DPACK by EGFR-expressing cancer cells was significantly higher than that of unmodified liposomes, and the liposomes accumulated in tumors and colocalized with EGFR. This simple, fast, effective and orientation-controllable technology for preparing antibody-modified liposomes will be useful for active targeting drug delivery. (Tokushima University Institutional Repository) ● Metadata: 116134 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijpharm.2021.120966 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34352337 ● Summary page in Scopus @ Elsevier: 2-s2.0-85112221934 (Tokushima University Institutional Repository: 116134, DOI: 10.1016/j.ijpharm.2021.120966, PubMed: 34352337, Elsevier: Scopus)

Proceeding of International Conference:

1.	AMI Hiramachi, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : Development of a novel DDS carrier having targetability to specific tissues by membrane fusion of exosome and liposome, 13th International congress on membranes and membrane processes (ICOM2023), Jul. 2023.
2.	sachika Yamashita, ami hiramachi, Tatsuya Fukuta, Mizune Ohzono, Eiji Majima and Kentaro Kogure : Antibody modification of exosome-based nanoparticles using improved Protein A to provide targeting ability, 13th International congress on membranes and membrane processes (ICOM2023), Jul. 2023.

Proceeding of Domestic Conference:

1.	NAKAMURA Seiko, Mizune Ohzono, Karen Yanagi and Kentaro Kogure : タクロリムス封入リポソームとイオントフォレシスを組み合わせた効果的な乾癬治療法の開発, 日本薬学会第144年会, Mar. 2024.
2.	HARUKI Konishi, Mizune Ohzono and Kentaro Kogure : 非接触型イオントフォレシスによる広範な皮内への薬物送達, 日本薬学会第144年会, Mar. 2024.
3.	Nath Manobendro Ray, Mizune Ohzono and Kentaro Kogure : タミンEコハク酸誘導アポトーシスとミトコンドリアおよび小胞体の関係, 第33回ビタミンE研究会, Jan. 2024.
4.	Kinari Hayashi, Mizune Ohzono, Michiyasu Nakao, Shigeki Sano and Kentaro Kogure : 新規ビタミンE誘導体の構造安定性と脂肪蓄積抑制効果, 第33回ビタミンE研究会, Jan. 2024.
5.	RINKA Kaneyama, Mizune Ohzono and Kentaro Kogure : がんワクチンの開発を目指したアジュバント修飾エクソソームの構築, 日本膜学会「第45年会」・「膜シンポジウム2023」合同大会, Nov. 2023.
6.	YUIKA Seto, YAMASAKI Misaki, Mizune Ohzono and Kentaro Kogure : ビタミンEコハク酸及びビタミンE共含有リポソームによる抗肥満効果の検討, 日本膜学会「第45年会」・「膜シンポジウム2023」合同大会, Nov. 2023.
7.	Kentaro Kogure, Chiho Ohtsuka, Mizune Ohzono and Naoshi Yamazaki : 微弱電流により誘起されるエンドサイトーシスのユニークな特性, 日本膜学会「第45年会」・「膜シンポジウム2023」合同大会, Nov. 2023.
8.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : 粒子径制御脂質ナノ粒子の脳虚血再灌流領域への効率的送達, 第44回生体膜と薬物の相互作用シンポジウム, Oct. 2023.
9.	林生成, 山﨑美沙季, Mizune Ohzono, Michiyasu Nakao, Shigeki Sano and Kentaro Kogure : 安定性を向上させた新規ビタミン E 誘導体の脂肪蓄積抑制効果, 日本ビタミン学会第 75 回大会, Jun. 2023.
10.	瀬戸唯加, 山﨑美沙季, Mizune Ohzono and Kentaro Kogure : ビタミン E コハク酸 / ビタミン E 共含有リポソーム投与が肥満モデルマウスの脂肪蓄積に与える影響, 日本ビタミン学会第 75 回大会, Jun. 2023.
11.	Nath Manobendro Ray, Mizune Ohzono and Kentaro Kogure : ビタミン E コハク酸誘導アポトーシスには細胞内 Ca2+ とミトコンドリアが関与する, 日本ビタミン学会第 75 回大会, Jun. 2023.
12.	HIBIKI Yoshida, Mizune Ohzono and Kentaro Kogure : 皮内コラーゲン合成促進を目指したアスコルビン酸封入リポソームのイオントフォレシス, 日本薬剤学会第38年会, May 2023.
13.	HARUKI Konishi, Mizune Ohzono and Kentaro Kogure : 非接触型イオントフォレシスによる高分子薬物の皮内送達, 日本薬剤学会第38年会, May 2023.
14.	YAMASAKI Misaki, YUIKA Seto, Mizune Ohzono, Michiyasu Nakao, Shigeki Sano and Kentaro Kogure : ジカルボン酸構造の最適化による安全で脂肪蓄積抑制作用を有する新規ビタミンE誘導体の開発, 日本薬学会第143年会, Mar. 2023.
15.	Kinari Hayashi, YAMASAKI Misaki, Mizune Ohzono, Michiyasu Nakao, Shigeki Sano and Kentaro Kogure : 構造改変によるビタミンE誘導体の安定性の向上と脂肪蓄積抑制効果, 第32回ビタミンE研究会, Jan. 2023.
16.	YUIKA Seto, YAMASAKI Misaki, Mizune Ohzono and Kentaro Kogure : ビタミンE/ビタミンEコハク酸共含有リポソームが肥満マウスに及ぼす影響, 第32回ビタミンE研究会, Jan. 2023.
17.	Nath Manobendro Ray, Mizune Ohzono, Michiyasu Nakao, Shigeki Sano and Kentaro Kogure : 炭素数一つの違いがビタミンE誘導体の細胞毒性を左右する, 第32回ビタミンE研究会, Jan. 2023.
18.	SACHIKA Yamashita, AMI Hiramachi, Tatsuya Fukuta, Mizune Ohzono, Eiji Majima and Kentaro Kogure : 改変型Protein Aを用いたエクソソームとエクソソーム基盤ナノ粒子の抗体修飾による標的化能の付与, 膜シンポジウム2022, Nov. 2022.
19.	AMI Hiramachi, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : エクソソームとリポソームのキメラナノ粒子構築と脳血管内皮細胞取り込みの検討, 膜シンポジウム2022, Nov. 2022.
20.	RINKA Kaneyama, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : 細胞外小胞Exosomeの皮内送達による皮膚炎症抑制の検討, 膜シンポジウム2022, Nov. 2022.
21.	Nath Manobendro Ray, Mizune Ohzono and Kentaro Kogure : ビタミンE誘導体の細胞毒性に寄与する構造特性とそのメカニズムの検討, 膜シンポジウム2022, Nov. 2022.
22.	MANOBENDRO NATH RAY, Mizune Ohzono and Kentaro Kogure : ビタミン E 誘導体の細胞毒性を左右する構造特性とメカニズムの検討, 第373回脂溶性ビタミン総合研究委員会, Sep. 2022.
23.	Ara Tabassum, Mizune Ohzono and Kentaro Kogure : 抗酸化ナノ粒子によるCCl4誘導酸化ストレス肝障害抑制効果, フォーラム2022, Aug. 2022.
24.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : 脳保護薬FK506封入脂質ナノ粒子の粒子径制御を介した脳虚血/再灌流治療効果の向上, 遺伝子・デリバリー研究会第21回シンポジウム，第20回夏季セミナー, Aug. 2022.
25.	YUIKA Seto, YAMASAKI Misaki, Mizune Ohzono and Kentaro Kogure : ビタミン E によるビタミン E コハク酸の細胞毒性制御と脂肪蓄積抑制, 日本ビタミン学会第74回大会, Jun. 2022.
26.	Mizune Ohzono, Misaki Yamasaki, Yuika Seto, Michiyasu Nakao, Shigeki Sano and Kentaro Kogure : 安全で脂肪蓄積抑制作用を有する新規ビタミンE誘導体の開発, 日本ビタミン学会第74回大会, Jun. 2022.
27.	YUIKA Seto, Mizune Ohzono and Kentaro Kogure : 細胞毒性を制御したビタミンEコハク酸リポソーム製剤による抗肥満効果の検討, 第 372 回脂溶性ビタミン総合研究委員会プログラム, Jun. 2022.
28.	Riho Tashima, Yuma Hirata, Mizune Ohzono, Tatsuya Fukuta, Eiji Majima and Kentaro Kogure : 改良型ProteinAを用いたリポソームへの簡便で効率的な抗体修飾法の開発, 日本膜学会第44年会, Jun. 2022.
29.	SACHIKA Yamashita, AMI Hiramachi, Tatsuya Fukuta, Mizune Ohzono, Eiji Majima and Kentaro Kogure : 改変型Protein Aを用いた抗体修飾によるエクソソーム基盤ナノ粒子への標的化能の付与, 日本膜学会第44年会, Jun. 2022.
30.	HIBIKI Yoshida, Mizune Ohzono and Kentaro Kogure : 皮内コラーゲン合成促進を目指したイオントフォレシスによるパルミトイルアスコルビン酸封入リポソームの皮内送達, 日本薬剤学会第37年会, May 2022.
31.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : FK506封入脂質ナノ粒子の粒子径制御による脳虚血/再灌流障害に対する治療効果の向上, 日本薬剤学会第37年会, May 2022.
32.	Ara Tabassum, Ono Satoko, Mizune Ohzono and Kentaro Kogure : Hepatoprotective effects of ferulic acid liposomal formulation against CCl4-induced oxidative liver damage, 第75回日本酸化ストレス学会学術集会, May 2022.
33.	Mizune Ohzono, Akira Watanabe, Yasuo Shinohara and Takenori Yamamoto : ミトコンドリアカルシウムユニポーターのコイルドコイルドメインの構造機能解析, 日本薬学会第142年会, Mar. 2022.
34.	Nath Manobendro Ray, Yamasaki Misaki, Mizune Ohzono and Kentaro Kogure : Apoptogenic Activity of Tocopheryl Esters Depends on their Structure, 日本薬学会第142年会,, Mar. 2022.
35.	Kohki Michiue, 高山健太郎, 林良雄, Mizune Ohzono and Kentaro Kogure : イオントフォレシスによるマイオスタチン阻害ペプチドの筋内送達による筋量増大, 遺伝子・デリバリー研究会第20回シンポジウム, Dec. 2021.
36.	Mizune Ohzono, 渡辺朗, Yasuo Shinohara and Takenori Yamamoto : ミトコンドリアカルシウムユニポーターのコイルドコイルドメインの構造機能解析, 膜シンポジウム2021, Nov. 2021.
37.	Ami Hiramachi, Akina Nishikawa, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : エクソソームとリポソームの膜融合による組織指向性を有する新規DDSキャリアの構築, 膜シンポジウム2021, Nov. 2021.
38.	Sachika Yamashita, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : 改変型Protein Aを用いた抗体修飾によるエクソソームへの標的化能の付与, 膜シンポジウム2021, Nov. 2021.
39.	Rinka Kaneyama, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : ヒト骨髄由来間葉系幹細胞Exosomeの皮内送達による皮膚炎症抑制の試み, 膜シンポジウム2021, Nov. 2021.
40.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : 粒子径制御FK506内封脂質ナノ粒子の構築と脳梗塞部位への送達効率の向上, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
41.	Kentaro Kogure, Chiho Ohtsuka, Tasuku Torao, Miyuki Mimura, Mizune Ohzono and Tatsuya Fukuta : 微弱電流が誘導するユニークなエンドサイトーシスの特性, 第42回生体膜と薬物の相互作用シンポジウム, Oct. 2021.
42.	Mizune Ohzono, Nath Manobendoro Ray, YAMASAKI Misaki, Yuika Seto, Michiyasu Nakao, Tatsuya Fukuta, Shigeki Sano and Kentaro Kogure : ビタミンE誘導体による細胞死誘導機構の解明と安全な抗肥満薬開発への展開, 第42回生体膜と薬物の相互作用シンポジウム, Oct. 2021.
43.	Kentaro Kogure, Yuika Seto, YAMASAKI Misaki and Mizune Ohzono : 脂肪蓄積抑制作用を有する新規ビタミンEエステル体の開発, 第368 回脂溶性ビタミン総合研究委員会, Jun. 2021.
44.	Ara Tabassum, Ono Satoko, Hasan Mahadi, Mizune Ohzono, Tatsuya Fukuta and Kentaro Kogure : Protective effects of ferulic acid liposomal formulation on CCl4-induced liver damage, 日本薬学会第142年会, Mar. 2021.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Search by Researcher Number (60909498)